Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mulligan

Showing results (451-460 of 529) with videos related to

Pageof 53
Sort By:
Frontiers in Immunology|March 13, 2023
Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Annals of Clinical and Translational Neurology|May 7, 2024
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccinationIlya Kister, Ryan Curtin, Amanda L Piquet, et al.
Mbio|June 30, 2023
Optimized quantification of intra-host viral diversity in SARS-CoV-2 and influenza virus sequence dataA E Roder, K E E Johnson, M Knoll, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2014
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humansAli H Ellebedy, Florian Krammer, Gui-Mei Li, et al.
The New England Journal of Medicine|April 8, 2026
Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 TrialEmmanuel Feroldi, Mark J Mulligan, Kawsar R Talaat, et al.
Vaccine|March 3, 2001
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humansT G Evans, M J McElrath, T Matthews, et al.
Nature Immunology|December 17, 2013
Molecular signatures of antibody responses derived from a systems biology study of five human vaccinesShuzhao Li, Nadine Rouphael, Sai Duraisingham, et al.
Vaccine|December 17, 2023
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adultsLisa A Jackson, Jack T Stapleton, Emmanuel B Walter, et al.
Vaccines|July 30, 2020
Alterations in the Human Plasma Lipidome in Response to Tularemia VaccinationKristal M Maner-Smith, Johannes B Goll, Manoj Khadka, et al.
JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.
Pageof 53

Showing results (451-460 of 529) with videos related to

Sort By:
Pageof 53
Frontiers in Immunology|March 13, 2023
Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studiesJohannes B Goll, Steven E Bosinger, Travis L Jensen, et al.
Annals of Clinical and Translational Neurology|May 7, 2024
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccinationIlya Kister, Ryan Curtin, Amanda L Piquet, et al.
Mbio|June 30, 2023
Optimized quantification of intra-host viral diversity in SARS-CoV-2 and influenza virus sequence dataA E Roder, K E E Johnson, M Knoll, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 27, 2014
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humansAli H Ellebedy, Florian Krammer, Gui-Mei Li, et al.
The New England Journal of Medicine|April 8, 2026
Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 TrialEmmanuel Feroldi, Mark J Mulligan, Kawsar R Talaat, et al.
Vaccine|March 3, 2001
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humansT G Evans, M J McElrath, T Matthews, et al.
Nature Immunology|December 17, 2013
Molecular signatures of antibody responses derived from a systems biology study of five human vaccinesShuzhao Li, Nadine Rouphael, Sai Duraisingham, et al.
Vaccine|December 17, 2023
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adultsLisa A Jackson, Jack T Stapleton, Emmanuel B Walter, et al.
Vaccines|July 30, 2020
Alterations in the Human Plasma Lipidome in Response to Tularemia VaccinationKristal M Maner-Smith, Johannes B Goll, Manoj Khadka, et al.
JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.
Pageof 53